Date: 2026-06-11Category: Press ReleaseState: Union GovernmentCountry: India
Scientific Conclave on Indian Pharmacopoeia (IP) 2026 Held in Haridwar; Highlights Role of Pharmacopoeial Standards in Strengthening Pharmaceutical Quality
**Executive Summary**
The Indian Pharmacopoeia Commission (IPC) organized a Scientific Conclave on June 10, 2026, in Haridwar to prepare the industry for the implementation of Indian Pharmacopoeia (IP) 2026. The event focused on "Strengthening Pharmaceutical Manufacturing through Pharmacopoeial Standards and Quality Compliance," providing handholding support to manufacturers to ensure the production of quality-assured medicines. Key outcomes included enhanced stakeholder engagement and the dissemination of technical guidance on evolving regulatory requirements.
**Key Points / Main Content**
**Objectives and Strategic Context**
* **Capacity Building:** The conclave aimed to strengthen industry preparedness for IP 2026 through awareness and capacity-building initiatives.
* **Regional Focus:** Haridwar was selected as the venue due to its status as a leading pharmaceutical manufacturing hub that effectively utilizes IP standards and reference substances.
* **Collaborative Framework:** The event was a joint effort between the IPC and the Association of Devbhumi Pharma Industries (ADPI) to foster collaboration between industry and standard-setting bodies.
**Technical Developments in IP 2026**
* **Standard Advancements:** Discussions highlighted key advancements incorporated into IP 2026, emphasizing scientifically validated quality standards.
* **Core Technical Areas:** Specialized sessions covered reference substances, microbiological quality requirements, biological standards, and analytical investigations.
* **Quality Management:** Participants received practical insights into the application of IP standards within quality management systems and manufacturing control.
**Stakeholder Engagement and Implementation**
* **Interactive Support:** A dedicated session allowed industry representatives to seek direct clarifications from IPC scientists regarding technical and regulatory implementation aspects.
* **Global Leadership:** The IPC underscored the role of IP standards in supporting India's growing stature as a global leader in the pharmaceutical sector.
* **Compliance and Safety:** The conclave emphasized that consistent adoption of IP standards is critical for regulatory compliance and safeguarding public health.
**Impact Analysis**
**Pharmaceutical Manufacturing Units**
**Impact**
Manufacturers receive direct handholding support and technical guidance to navigate the transition to IP 2026 standards, reducing implementation hurdles.
**Action Required**
Units must align their manufacturing processes with the updated provisions of IP 2026 and participate in ongoing capacity-building initiatives.
**Quality Control (QC) and Quality Assurance (QA) Professionals**
**Impact**
These professionals gain updated knowledge on recent developments in biological standards, microbiological requirements, and analytical investigations.
**Action Required**
QA/QC teams must adopt the best practices for quality assurance and updated analytical methods discussed during the technical deliberations.
**Regulatory Authorities (CDSCO and State Licensing)**
**Impact**
Regulators benefit from a platform that facilitates dialogue with the industry, ensuring smoother enforcement of quality-assured manufacturing practices.
**Action Required**
Authorities must continue to monitor compliance with IP 2026 standards and facilitate the manufacture of quality-assured medicines through continued stakeholder engagement.
Key Entities Referenced
Indian Pharmacopoeia (IP) 2026: The forthcoming edition of official pharmaceutical standards in India, used to ensure the quality, safety, and efficacy of medicines manufactured within the country.
Indian Pharmacopoeia Commission (IPC): The autonomous body under the Ministry of Health and Family Welfare responsible for establishing drug standards and organizing capacity-building initiatives for the industry.
Uttarakhand: A primary pharmaceutical manufacturing hub in India and the central location for the conclave aimed at fostering regional adoption of quality-assured manufacturing practices.
Association of Devbhumi Pharma Industries (ADPI): A pharmaceutical manufacturing association that collaborated with regulators to facilitate industry awareness and compliance with updated pharmacopoeial standards.
Ministry of Health and Family Welfare
Scientific Conclave on Indian Pharmacopoeia (IP)
2026 Held in Haridwar; Highlights Role of
Pharmacopoeial Standards in Strengthening
Pharmaceutical Quality
IPC Strengthens Industry Preparedness for IP 2026 Through
Awareness and Capacity-Building Initiatives
IP 2026 Conclave Encourages Wider Adoption of
Pharmacopoeial Standards, Provides Handholding Support
to Pharmaceutical Industry
IPC Advances Stakeholder Engagement to Foster
Pharmaceutical Quality and Manufacture of Quality-Assured
Medicines
प्रव तथ: 11 JUN 2026 12:07PM by PIB Delhi
The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health
and Family Welfare, Government of India, organized a Scientific Conclave and Interactive Session on
Indian Pharmacopoeia (IP) 2026 “Strengthening Pharmaceutical Manufacturing through Pharmacopoeial
Standards and Quality Compliance” at Haridwar yesterday, in collaboration with the Association of
Devbhumi Pharma Industries (ADPI) and affiliated pharmaceutical manufacturing associations of
Uttarakhand. The conclave was organized with the objective of enhancing awareness on the provisions of
IP 2026 and promoting quality compliance across the pharmaceutical manufacturing sector.Uttarakhand is one of India’s leading pharmaceutical manufacturing hubs and has been among the states
effectively utilizing the IP and Indian Pharmacopoeia Reference Substances for ensuring the quality,
safety, and efficacy of medicines. Recognizing the state’s significant contribution to pharmaceutical
manufacturing, the conclave was organized to further strengthen industry awareness, support compliance
with pharmacopoeial requirements, and promote the consistent adoption of IP standards across the
pharmaceutical sector, thereby providing handholding support to pharmaceutical manufacturers and other
stakeholders in the state.
The programme brought together representatives from pharmaceutical manufacturing units, quality control
and quality assurance professionals, regulatory authorities, analytical scientists, and drug testing
laboratory personnel to deliberate on recent developments in pharmacopoeial standards and their
implementation in the pharmaceutical industry.
The inaugural session commenced with a welcome address by Shri Sandeep Jain, Chairman, ADPI.
Addressing the gathering, he emphasized the importance of collaboration between industry and standard-
setting bodies in strengthening pharmaceutical quality systems.
The session was also addressed by Shri Sidharth Sahai Malhotra, Assistant Drugs Controller (India),
CDSCO, Dehradun, and Shri Tajber Singh, Drug Controller and State Licensing Authority, Uttarakhand,
who highlighted the critical role of pharmacopoeial standards in ensuring regulatory compliance and
safeguarding public health.Delivering the Chief Guest address, Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC,
underscored the pivotal role of the IP in establishing scientifically validated quality standards for
medicines and supporting India’s growing stature as a global pharmaceutical leader. He highlighted the
key advancements incorporated in IP 2026 and emphasized the importance of industry participation in
ensuring the effective implementation of pharmacopoeial requirements.
Following the inaugural session, a series of technical deliberations and knowledge-sharing interactions
were conducted on key aspects of the IP, including recent developments in pharmacopoeial standards,
reference substances, microbiological quality requirements, quality management systems, analytical
investigations and biological standards. The sessions provided participants with practical insights into the
application of IP standards in pharmaceutical manufacturing and quality control.A dedicated interactive session provided participants with an opportunity to engage directly with IPC
scientists and seek clarifications on technical, regulatory and implementation-related aspects of IP 2026.
The discussions reflected the industry’s keen interest in understanding evolving pharmacopoeial
requirements and adopting best practices for quality assurance.
The conclave reaffirmed IPC’s commitment to fostering greater awareness of pharmacopoeial standards
and strengthening collaboration with stakeholders to promote the manufacture of quality-assured
medicines. The event concluded with a networking session, enabling continued dialogue among
regulators, industry representatives, and scientific experts on advancing pharmaceutical quality and
compliance in Uttarakhand and across the country.
***
SR
HFW/Scientific Conclave on Indian Pharmacopoeia Held in Haridwar/11June 2026/1
(रलीज़ आईडी: 2271509) आगंतुक पटल : 1103
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही , Bengali , Tamil